Senior Medical Director, Oncology Clinical Development

Apply

Job Type

Full-time

Description

About Us

Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. The Company aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Its discovery process combines deep insights in clinically validated biological targets and differentiated chemistry with the goal of designing therapies for unmet needs.

About ELVN-001

ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region - Abelson ("BCR-ABL") gene fusion, the oncogenic driver for patients with chronic myeloid leukemia ("CML"). It targets the ATP-binding site of the ABL1 kinase domain and binds to a unique P-loop "folded-in" active conformation of ABL1, creating a narrow selectivity tunnel.

As a highly selective ATP-competitive inhibitor, ELVN-001 is differentiated from other ATP-competitive inhibitors in that it avoids off-target activity that may cause adverse events. With this potential additional safety margin, ELVN-001 may be optimally dosed to drive better efficacy. Additionally, ELVN-001 potentially represents a complementary option to allosteric BCR-ABL inhibitors (e.g., asciminib) due to its distinct mechanism of action and high selectivity which may play an increasingly important role in the standard of care for CML. Specifically, ELVN-001 was designed to have activity against emerging mutations known to confer resistance to allosteric TKIs, including asciminib. ELVN-001 was also designed to be a more attractive option for patients with comorbidities, on concomitant medications or desiring more freedom from stringent administration requirements.

ELVN-001 is currently being evaluated in the Phase 1 ENABLE clinical trial in heavily pretreated patients with CML, and we plan to initiate ENABLE-2, a 2L+ Phase 3 pivotal trial in the second half of 2026. The most recent data is available on the Program Presentation & Publications section of the website.

Role summary

The Senior Medical Director, Oncology Clinical Development will provide medical leadership for the clinical development of ELVN-001, with primary responsibility for medical oversight of early-phase oncology clinical trials. This individual will serve as the Study Responsible Physician for one or more studies and will play a key role in trial design, execution, safety monitoring, data interpretation, and clinical strategy.

Working in a highly collaborative small biotech environment, the Senior Medical Director will partner closely with cross-functional teams including Clinical Operations, Regulatory Affairs, Biostatistics, Clinical Pharmacology, Translational Sciences, and Medical Affairs to ensure high-quality and timely study execution. The role will also involve engagement with investigators, Key Opinion Leaders, and regulatory agencies, as well as contributions to scientific communications, publications, and broader program strategy.

The ideal candidate is a physician with deep oncology clinical development experience, strong scientific and clinical judgment, and the ability to thrive in a fast-paced, hands-on, and team-oriented environment.

Responsibilities: Areas that play to your strengths --

• Serve as Study Responsible Physician and provide medical oversight for one or more clinical studies supporting development of ELVN-001.
• Provide leadership, mentoring, and oversight to clinical scientists across assigned studies and development activities.
• Partner cross-functionally with Clinical Operations, Biostatistics, Clinical Pharmacology, Regulatory Affairs, Translational Sciences, Data Management, and other functions to ensure high-quality and timely study execution.
• Contribute to the design, conduct, analysis, and interpretation of early-phase oncology clinical trials.
• Lead ongoing medical monitoring activities, including safety review, dose-escalation assessment, data interpretation, and benefit-risk evaluation.
• Collaborate with clinical scientists and cross-functional partners on:\
• Preparation and review of clinical study documents, including protocols, amendments, investigator brochures, informed consent forms, and clinical study reports
• Medical review of clinical data and support of data review activities
• Preparation and presentation of clinical data for internal governance meetings, investigator meetings, scientific congresses, and external stakeholder interactions
• Development of study-related training materials and investigator communications
• Regulatory submissions and responses to Health Authority and Ethics Committee inquiries
• Build and maintain relationships with clinical investigators, cooperative groups, and Key Opinion Leaders.
• Contribute to clinical development strategy, study design, and lifecycle planning for oncology programs.
• Participate in preparation of scientific publications, abstracts, and presentations.
• Review and synthesize relevant scientific and medical literature to support program strategy and competitive awareness.
• Support broader clinical development and medical affairs initiatives as needed.

Requirements

• MD or equivalent medical degree required; board certification or specialization in Hematology/Oncology strongly preferred.
• Minimum of 7 years of clinical development experience in oncology drug development, including at least 5 years of industry experience.
• Experience with early-phase clinical trials.
• Experience in hematologic malignancies and/or targeted oncology therapies preferred.
• Demonstrated experience contributing to cross-functional clinical development teams in a matrixed environment.
• Strong scientific and clinical judgment with the ability to interpret complex clinical data.
• Excellent interpersonal, communication, and presentation skills, with the ability to effectively engage internal and external stakeholders.
• Proven ability to operate effectively in a fast-paced, collaborative biotech environment.
• Strong organizational skills, attention to detail, and problem-solving capabilities.

This is a full-time remote position (40 hours/week). Eastern or Central Time Zone preferred but not required. Occasional evening, weekend, holiday, and on-call work may be required as job duties demand. Occasional travel may be required.

The annual salary range Enliven reasonably and in good faith expects to pay for this position at the time of this posting is $260,000 - $305,000. The actual salary offered will be determined based on factors such as experience, qualifications, skills and expertise, geographic location, and other job-related factors permitted by law. Benefits are included and other incentives such as bonus and equity may be provided. This range is subject to change based on business needs, job scope changes, market conditions, and individual qualifications. Employees and applicants may request the pay range for their position or for a position to which they are applying.

Enliven Therapeutics is proud to be an equal opportunity employer. All employment offers are contingent upon the applicant successfully completing a background screen.

Notice to agencies: Our in-house Talent Acquisition Team manages all employment opportunities at Enliven. Agencies and independent recruiters must be approved as a vendor by our HR team. To protect the interests of all parties, Enliven will not accept unsolicited resumes, profiles, or biographies. Any unsolicited submissions will be considered referrals and become the property of Enliven. Contacting hiring managers, executives, or any member of the HR team will not influence vendor approval and is strongly discouraged. Repeated outreach may impact future consideration.